摩根大通发布研报称，信达生物(01801.HK)股价周一下跌约7%

Group 1 - Morgan Stanley reported that the stock price of Innovent Biologics (01801.HK) fell by approximately 7% on Monday, which may be related to the recently announced National Reimbursement Drug List (NRDL) [1] - The investment bank maintains an "Overweight" rating on the stock, with nearly 12 investment firms issuing buy ratings in the past 90 days, and the average target price over this period is HKD 118.29 [1] - CITIC Securities recently provided a buy rating for Innovent Biologics with a target price of HKD 136.12 [1] Group 2 - Innovent Biologics has a market capitalization of HKD 147.301 billion and ranks second in the biopharmaceutical II industry [2]